A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Inspire Medical Systems, Inc. INSP
Mixed broader-coverage candidate · Inspire Medical Systems, Inc.
On FrontierLab's discovery record since 2026-09-10 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-11), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 4.3% |
|---|---|
| Gross margin | 86.1% |
| Gross profits / assets | 0.84 |
| Rule of 40 | 10.3 |
| Net margin | 6% |
| Cash runway (months) | — |
| PEG | 0.1 |
| Price / sales | 2.2 |
Quality checklist
- ✗ Revenue growth — 4.3% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.84 (pass ≥ 0.33)
- ✓ Gross margin — 86.1% (pass ≥ 60%)
- ✓ Cash generation
- ✓ Share dilution — -1.9%
Fundamentals — snapshot as of 2026-09-11
| Stage | Established |
|---|---|
| Share issuance (YoY) | -1.9% · flat share count |
| Moat | — |
| TAM | — |
| P/E (trailing) | 14.7 |
| EPS (trailing) | $4.62 |
| Burn multiple | — |
| Gross-margin trend (pts) | 1.6 |
| Cash / assets | 0.35 |
| Net debt / EBITDA | -1.2 |
| Statements as of | Q2 FY2026 · filed 2026-08-03 |
Momentum context — a snapshot from 2026-09-11, not current
| Price at surface | $68.12 (as of 2026-09-11) |
|---|---|
| 52-week range | $38.91 – $147.03 |
| % off 52-wk high | -53.7% |
| RSI (14) | 70 |
| Relative volume | 2.1× |
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-11 (end-of-day). How grades are computed →